2. Signaling Pathways
  3. Immunology/Inflammation
  4. COX
  5. COX-2 Isoform
  6. COX-2 Inhibitor

COX-2 Inhibitor

COX-2 Inhibitors (319):

Cat. No. Product Name Effect Purity
  • HY-147811
    Heterophdoid A
    		Inhibitor
    Heterophdoid A (Compound 1) is an anti-inflammatory agent. Heterophdoid A inhibits NO production with an IC50 of 5.93 μM in BV-2 cells.
  • HY-161994
    COX-2-IN-47
    		Inhibitor
    COX-2-IN-47 (compound 6c ) is a selective COX-2 inhibitor with IC50 value of 0.03 μM. COX-2-IN-47 has antiedema activity.
  • HY-161513
    iNOS/COX-2-IN-1
    		Inhibitor
    iNOS/COX-2-IN-1 (Compound 12e) is an inhibitor of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). iNOS/COX-2-IN-1 inhibits the NF-κB and MAPKs signaling pathways and thus exerts anti-inflammatory effects.
  • HY-115966
    COX-1/2-IN-1
    		Inhibitor
    COX-1/2-IN-2 is a potent COX1/2 inhibitor. COX-1/2-IN-2 exhibits significant inhibitory effect against COX-1 and COX-2 inhibitor with IC50 values of 13.9 ± 3.21 µM and 6.4±0.74 µM, respectively.
  • HY-173518
    SIN 14
    		Inhibitor
    SIN 14, a derivative of Sinomenine (HY-15122), is an orally active HO-1 activator (KD = 17.2 μM). SIN 14 binds to the catalytic core domain of HO-1 and induces HO-1 activation in catalysis. SIN 14 significantly increases HO-1 stability. SIN 14 has anti-inflammatory effects and inhibits M1 macrophage polarization while promoting M2 polarization in LPS (Lipopolysaccharides)(HY-D1056)-induced RAW264.7 cells. SIN 14 inhibits inflammatory mediator production (eg: NO, IL-6, IL-1β and CCL2, inhibits production of ROS and down-regulates the expression of COX-2 and iNOS. SIN 14 can inhibit RA-related inflammatory edema in collagen-induced arthritis (ClA) mice.
  • HY-159562
    COX-2-IN-46
    		Inhibitor
    COX-2-IN-46 (compound 5m) is an anti-inflammatory agent with potent analgesic activity. COX-2-IN-46 exhibits a significant inhibitory effect on COX-2 (IC50=87.74 nM).
  • HY-149270
    COX-2-IN-31
    		Inhibitor
    COX-2-IN-31 (compound 7b) is an orally active and dual inhibitor of COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM). COX-2-IN-31 also inhibits transmembrane hCA IX(Ki=48.9 nM) and hCA XII(Ki=5.8 nM) activity. COX-2-IN-31 exhibits anti-inflammatory and analgesic activity.
  • HY-N16129
    Diplacone
    		Inhibitor
    Diplacone (DP) is a geranylated flavanone. Diplacone can be isolated from the unripe fruits of Paulownia tomentosa. Diplacone has anti-inflammatory, antiradical, cytoprotective, antibacterial and anticancer activities. Diplacone induces ferroptosis-mediated cell death by increasing mitochondrial Ca2+ Influx, ROS production and mitochondrial permeability transition. Diplacone significantly inhibits AChE and BChE activity with IC50s of 7.2  μM and 1.4 μM for hAChE and BChE, respectively. Diplacone can be used for chronic inflammatory diseases like inflammatory bowel diseases (IBD), cancers like lung cancer and Alzheimer’s disease research.
  • HY-115976
    COX-2-IN-10
    		Inhibitor
    COX-2-IN-10 is a potent COX-2 inhibitor. COX-2-IN-10 inhibits the production of PGE2 in concentration dependent manner (IC50=2.54 µM). COX-2-IN-10 inhibits the expression of iNOS and COX-2 on mRNA and protein level . COX-2-IN-10 inhibits the production of IL-6, TNF-α and IL-1β.
  • HY-N4230
    Clematomandshurica saponin B
    		Inhibitor
    Clematomandshurica saponins B shows significant inhibitory activity on cyclooxygenase-2 (IC50=2.58 mM).
  • HY-146704
    COX-2/sEH-IN-1
    		Inhibitor
    COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
  • HY-B0261A
    Meloxicam sodium
    		Inhibitor
    Meloxicam sodium is a non-steroidal anti-inflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively.
  • HY-W007539R
    2,4-Dihydroxybenzaldehyde (Standard)
    		Inhibitor
    2,4-Dihydroxybenzaldehyde (Standard) is the analytical standard of 2,4-Dihydroxybenzaldehyde. This product is intended for research and analytical applications. 2,4-Dihydroxybenzaldehyde is an endogenous metabolite. 2,4-Dihydroxybenzaldehyde is a pharmaceutical intermediate that can be used to synthesize various Schiff base compounds. 2,4-Dihydroxybenzaldehyde exhibits significant anti angiogenic, anti-inflammatory, and analgesic activities. 2,4-Dihydroxybenzaldehyde reduces the production of NO and ROS by inhibiting the expression of iNOS and COX-2. 2,4-Dihydroxybenzaldehyde is commonly used in the study of inflammatory conditions.
  • HY-168070
    COX-2-IN-48
    		Inhibitor
    COX-2-IN-48 (5-25), a COX-2 inhibitor with an IC50 of 51.7 nM for human COX-2, exerts anti-inflammatory and analgesic effects in various rodent models by inhibiting NF-κB pathway. COX-2-IN-48 (5-25) inhibits the degradation of IκB, the phosphorylation and nuclear translocation of NF-κB p65, and the expression of COX-2 and iNOS.
  • HY-149269
    COX-2-IN-30
    		Inhibitor
    COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC50=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC50=2.4 μM). COX-2-IN-30 also inhibits transmembrane hCA IX and hCA XII isoform with nanomolar calss Ki values. COX-2-IN-30 exhibits analgesic, anti-inflammatory, and ulcerogenic activities, and does not show acute gastric effect.
  • HY-N8469R
    cis-5-Dodecenoic acid (Standard)
    		Inhibitor
    cis-5-Dodecenoic acid (Standard) is the analytical standard of cis-5-Dodecenoic acid (HY-N8469). This product is intended for research and analytical applications. cis-5-Dodecenoic acid is an inhibitor of COX-I and COX-II with anti-inflammatory activity. cis-5-Dodecenoic acid reduces prostaglandin synthesis by inhibiting COX enzyme activity and is involved in the fatty acid -β oxidative metabolic pathway. The metabolic rate of cis-5-Dodecenoic acid is significantly lower than that of saturated fatty acids. cis-5-Dodecenoic acid can be used in the research of anti-inflammation, fatty acid metabolism mechanisms and related physiological and pathological processes.
  • HY-B0808A
    Oxaprozin potassium
    		Inhibitor
    Oxaprozin potassium is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin potassium also inhibits the activation of NF-κB. Oxaprozin potassium induces cell apoptosis. Oxaprozin potassium shows anti-inflammatory activity. Oxaprozin potassium-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties.
  • HY-N2599
    Taraxerol acetate
    		Inhibitor
    Taraxerol acetate is a COX-1 and COX-2 inhibitor with IC50 values of 116.3 μM and 94.7 μM, respectively. Taraxerol acetate the has the anticancer potential and induces cell apoptosis.
  • HY-147719
    COX-2-IN-16
    		Inhibitor
    COX-2-IN-16 (compound 2b) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 102 µM. COX-2-IN-16 inhibits the NO production. COX-2-IN-16 shows anti-inflammatory activity.
  • HY-170932
    EGFR/COX-2-IN-1
    		Inhibitor
    EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor. EGFR/COX-2-IN-1 inhibits EGFRWT, EGFRT790M, COX-1 and COX-2 with IC50s of 0.12, 0.076, 20.1 and 1.52 μM respectively. EGFR/COX-2-IN-1 inhibits and with IC50s of , respectively. EGFR/COX-2-IN-1 inhibits MCF-7, HT-29 and A-549 with IC50s of 1.20, 5.14 and 14.81 μM, respectively. EGFR/COX-2-IN-1 displays Apoptosis induction by up-regulating Bax and down-regulating Bcl-2 protein levels. EGFR/COX-2-IN-1 results in a significant increase in the percentage of cells at the G2/M in MFC-7 cells. EGFR/COX-2-IN-1 exhibits broad-spectrum antitumor effects.